Establishing and characterizing patient-derived xenografts using pre-chemotherapy percutaneous biopsy and post-chemotherapy surgical samples from a prospective neoadjuvant breast cancer study

[1]  Krishna R. Kalari,et al.  Tumor Sequencing and Patient-Derived Xenografts in the Neoadjuvant Treatment of Breast Cancer , 2017, Journal of the National Cancer Institute.

[2]  Hans Clevers,et al.  Interrogating open issues in cancer precision medicine with patient-derived xenografts , 2017, Nature Reviews Cancer.

[3]  Donna Neuberg,et al.  The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. , 2016, Cancer cell.

[4]  Joshua M. Korn,et al.  High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response , 2015, Nature Medicine.

[5]  Ann M. Moyer,et al.  Exome sequencing reveals frequent deleterious germline variants in cancer susceptibility genes in women with invasive breast cancer undergoing neoadjuvant chemotherapy , 2015, Breast Cancer Research and Treatment.

[6]  Sohrab P. Shah,et al.  Dynamics of genomic clones in breast cancer patient xenografts at single-cell resolution , 2014, Nature.

[7]  J. Visvader,et al.  Patient-derived xenograft models of breast cancer and their predictive power , 2015, Breast Cancer Research.

[8]  Krishna R. Kalari,et al.  Loss of heterozygosity at the CYP2D6 locus in breast cancer: implications for germline pharmacogenetic studies. , 2015, Journal of the National Cancer Institute.

[9]  Gideon Blumenthal,et al.  Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis , 2014, The Lancet.

[10]  John M S Bartlett,et al.  Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. , 2014, Archives of pathology & laboratory medicine.

[11]  Manuel Hidalgo,et al.  Patient-derived xenograft models: an emerging platform for translational cancer research. , 2014, Cancer discovery.

[12]  P. Colombo,et al.  Breast tumor PDXs are genetically plastic and correspond to a subset of aggressive cancers prone to relapse , 2013, Molecular oncology.

[13]  Marc Coram,et al.  Patient-derived xenografts of triple-negative breast cancer reproduce molecular features of patient tumors and respond to mTOR inhibition , 2014, Breast Cancer Research.

[14]  P. Johnston,et al.  Cancer drug resistance: an evolving paradigm , 2013, Nature Reviews Cancer.

[15]  Chad A Shaw,et al.  A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models. , 2013, Cancer research.

[16]  Samir J. Courdy,et al.  Patient‐Derived Models of Human Breast Cancer: Protocols for In Vitro and In Vivo Applications in Tumor Biology and Translational Medicine , 2013, Current protocols in pharmacology.

[17]  Jenny C. Chang,et al.  Patient-derived breast tumor xenografts facilitating personalized cancer therapy , 2013, Breast Cancer Research.

[18]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumours , 2013 .

[19]  A. Giordano,et al.  Critical choices for modeling breast cancer in transgenic mouse models , 2012, Journal of cellular physiology.

[20]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumors , 2012, Nature.

[21]  L. Collette,et al.  O-0028 Adjuvant Folfox4 +/- Cetuximab in KRAS Wild-Type Patients with Resected Stage III Colon Cancer Results from the Petacc8 Intergroup Trial , 2012 .

[22]  Aik Choon Tan,et al.  Patient-derived tumour xenografts as models for oncology drug development , 2012, Nature Reviews Clinical Oncology.

[23]  R. Peto,et al.  Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. , 2012, Lancet.

[24]  O. Myklebost,et al.  Preclinical xenograft models of human sarcoma show nonrandom loss of aberrations , 2012, Cancer.

[25]  A. Vincent-Salomon,et al.  Modeling of response to endocrine therapy in a panel of human luminal breast cancer xenografts , 2012, Breast Cancer Research and Treatment.

[26]  Jean-Pierre Gillet,et al.  Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance , 2011, Proceedings of the National Academy of Sciences.

[27]  Mark T. W. Ebbert,et al.  Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes , 2011, Nature Medicine.

[28]  Davide Corà,et al.  A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. , 2011, Cancer discovery.

[29]  R. Gelber,et al.  Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011 , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[30]  L. Esserman,et al.  A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer. , 2011, JAMA.

[31]  Anthony Rhodes,et al.  American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  M. Loda,et al.  Establishment and genomic characterization of mouse xenografts of human primary prostate tumors. , 2010, The American journal of pathology.

[33]  Joshua F. McMichael,et al.  Genome Remodeling in a Basal-like Breast Cancer Metastasis and Xenograft , 2010, Nature.

[34]  Peter Kampstra,et al.  Beanplot: A Boxplot Alternative for Visual Comparison of Distributions , 2008 .

[35]  Peter Kraft,et al.  Heterogeneity of Breast Cancer Associations with Five Susceptibility Loci by Clinical and Pathological Characteristics , 2008, PLoS genetics.

[36]  J. Rosen,et al.  Modelling breast cancer: one size does not fit all , 2007, Nature Reviews Cancer.

[37]  A. Vincent-Salomon,et al.  A New Model of Patient Tumor-Derived Breast Cancer Xenografts for Preclinical Assays , 2007, Clinical Cancer Research.

[38]  G. Hortobagyi,et al.  Overview of resistance to systemic therapy in patients with breast cancer. , 2007, Advances in experimental medicine and biology.

[39]  Wen-Lin Kuo,et al.  A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. , 2006, Cancer cell.

[40]  R. Hruban,et al.  An In vivo Platform for Translational Drug Development in Pancreatic Cancer , 2006, Clinical Cancer Research.

[41]  K. Akashi,et al.  Development of functional human blood and immune systems in NOD/SCID/IL2 receptor γ chainnull mice , 2005 .

[42]  Eric R. Prossnitz,et al.  A Transmembrane Intracellular Estrogen Receptor Mediates Rapid Cell Signaling , 2005, Science.

[43]  K. Akashi,et al.  Development of functional human blood and immune systems in NOD/SCID/IL2 receptor {gamma} chain(null) mice. , 2005, Blood.

[44]  C. Zuiani,et al.  Locally advanced breast cancer: comparison of mammography, sonography and MR imaging in evaluation of residual disease in women receiving neoadjuvant chemotherapy , 2004, European Radiology.

[45]  Korbinian Strimmer,et al.  APE: Analyses of Phylogenetics and Evolution in R language , 2004, Bioinform..

[46]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[47]  John N. Hutchinson,et al.  Transgenic mouse models of human breast cancer , 2000, Oncogene.

[48]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[49]  A. Cesano,et al.  Growth characteristics and metastatic properties of human breast cancer xenografts in immunodeficient mice. , 1998, The American journal of pathology.